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A
rtificial transcriptional modulators have for decades
served as powerful tools for parsing the mechanistic
details of the transcriptional process. In recent
years, however, these tools have grown in impor-
tance as the connections between human disease
and transcriptional misregulation have strengthened.
Towards that end, much effort has been focused upon the
discovery of molecules that directly interfere with the ability
of a DNA-bound transcriptional activator to interact with its
binding partners, thus serving to inhibit part or all of the
activator’s regulatory function.
There are two primary challenges that hamper the devel-
opment of inhibitors of transcriptional activators. The first is
commonly encountered in targeting a protein-protein inter-
action, that the interaction surface is often large with limited
topology. An additional complication is that few of these
interaction surfaces are well characterized, with little struc-
tural or binding detail available that would facilitate design
efforts. A second roadblock is that for many transcriptional
activators, the direct binding partners responsible for the rel-
evant transcriptional activity are not known. Not surpris-
ingly, this can cause considerable difficulties with regard to
discovery of inhibitors and, further, in defining their precise
mechanism.
In this issue of Biopolymers, we see several approaches
aimed at overcoming the hurdles outlined above for the dis-
covery of transcriptional inhibitors targeted to block the
function of particular transcriptional activators. In the first
paper, Paramjit Arora of New York University describes the
state of the field of helix mimetics as applied to transcrip-
tional inhibition. This includes, for example, the so-called
hydrocarbon stapled and hydrogen bond surrogate helices
that are able to target much larger binding surfaces than
small molecules and are readily accessible synthetically. Bog-
dan Olenyuk of the University of Southern California has
successfully developed natural product-derived small mole-
cules called ETPs that interact with the CH1 domain of the
coactivator CBP and in doing so, down-regulate genes con-
trolled by the activator HIF1a, an activator that regulates the
hypoxic response in tumors. In contrast to many activator-
coactivator interactions, the interaction between HIF1a and
the CH1 domain is well-characterized, facilitating these stud-
ies. Naoaki Fujii of St Jude Children’s Research Hospital
describes a structure-activity study of small molecules that
selectively inhibit transcription regulated by the oncogenic
transcription factor Gli1. Finally, Caleb Bates and William
Pomerantz at the University of Michigan describe converting
a group of small molecules originally characterized as tran-
scriptional activators when targeted to DNA into inhibitors
of the activators cJun and MLL. As these papers highlight,
there has been great progress in the march towards effective
transcriptional inhibitors and the next few years should bring
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